Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Urovant Sciences GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of overactive bladder (OAB) with or without urgency urinary incontinence
Symptoms of OAB for at least 3 months prior to the Baseline Visit
Willing and able to complete electronic patient-reported outcomes questionnaires monthly for a minimum of 1 year
Previous exposure to anticholinergics or mirabegron monotherapy and/or mirabegron plus solifenacin combination therapy prior to initiation of vibegron
You may not be if
Any contraindication to the use of vibegron per the United States label
History of OAB treatment with botulinum toxin A; sacral neuromodulation; percutaneous tibial nerve stimulation; external beam radiation therapy; urinary stents within the last 6 months; pelvic or lower urinary tract surgery within the last 6 months; and urethral catheterizations within the last 3 months prior to the Baseline Visit
History of mixed incontinence where stress incontinence is the predominant form (as determined by the investigator)
Participants at risk of urinary retention (as determined by the investigator)
Neurologic conditions associated with OAB symptoms, e.g., multiple sclerosis
Pregnant or breastfeeding or plans to do so during the study
Use of vibegron prior to the Baseline Visit either prescribed or in a previous vibegron clinical trial where the participant was on vibegron
Anyone who, at the discretion of the investigator, is not suitable for treatment with a beta 3 agonist for OAB for any reason
